418 G.A. Cabral and A. Staab
Gross G, Roussaki A, Ikenberg H, Drees N (1991) Genital warts do not respond to systemic
recombinant interferon alpha-2a treatment during cannabis consumption. Dermato-
logica 183:203–207
Guarisco JL, Cheney ML, LeJeune FE Jr, Reed HT (1988) Isolated uvulitis secondary to
marijuana use. Laryngoscope 98:1309–1312
Harkess J, Gildon B, Istre GR (1989) Outbreaks of hepatitis A among illicit drug users,
Oklahoma, 1984–87. Am J Public Health 79:463–466
Herring AC, Koh WS, Kaminski NE (1998) Inhibition of the cyclic AMP signaling cascade
and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally
CNS-active cannabinoid. Biochem Pharmacol 55:1013–1023
Hollister LE (1986) Health aspects of cannabis. Pharmacol Rev 38:1–20
Howlett AC (1985) Cannabinoid inhibition of adenylate cyclase. Biochemistry of the re-
sponse in neuroblastoma cell membranes. Mol Pharmacol 27:429–436
Howlett AC (1995) Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol
35:607–634
Howlett AC, Fleming RM (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology
of the response in neuroblastoma cell membranes. Mol Pharmacol 26:532–538
Howlett AC, Qualy JM, Khachatrian LL (1986) Involvement of Gi in the inhibition of adeny-
late cyclase by cannabimimetic drugs. Mol Pharmacol 29:307–313
Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham
M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of
Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161–
202
Jan TR, Rao GK, Kaminski NE (2002) Cannabinol enhancement of interleukin-2 (IL-2)
expression by T cells is associated with an increase in IL-2 distal nuclear factor of
activated T cell activity. Mol Pharmacol 61:446–454
Jeon YJ, Yang KH, Pulaski JT, Kaminski NE (1996) Attenuation of inducible nitric oxide
synthase gene expression by delta-9-tetrahydrocannabinol is mediated through the
inhibition of nuclear factor- kappa B/Rel activation. Mol Pharmacol 50:334–341
Juel-Jensen BE (1972) Cannabis and recurrent herpes simplex. Br Med J 4:296
Kagen SL,Kurup VP,Sohnle PG,FinkJN(1983) Marijuana smokingand fungal sensitization.
J Allergy Clin Immunol 71:389–393
Kaminski NE (1998) Regulation of the cAMP cascade, gene expression and immune function
by cannabinoid receptors. J Neuroimmunol 83:124–132
Kaminski NE, Abood ME, Kessler FK, Martin BR, Schatz AR (1992) Identification of
a functionally relevant cannabinoid receptor on mouse spleen cells that is involved
in cannabinoid-mediated immune modulation. Mol Pharmacol 42:736–742
Kaminski NE, Koh WS, Yang KH, Lee M, Kessler FK (1994) Suppression of the humoral im-
mune response by cannabinoids is partially mediated through inhibition of adenylate
cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem Pharma-
col 48:1899–1908
Kaslow RA, Blackwelder WC, Ostrow DG, Yerg D, Palenicek J, Coulson AH, Valdiserri RO
(1989) No evidence for a role of alcohol or other psychoactive drugs in accelerating
immunodeficiency in HIV-1-positive individuals. A report from the Multicenter AIDS
Cohort Study. JAMA 261:3424–3429
Kawakami Y, Klein TW, Newton C, Djeu JY, Dennert G, Specter S, Friedman H (1988a)
Suppression by cannabinoids of a cloned cell line with natural killer cell activity. Proc
Soc Exp Biol Med 187:355–359
Kawakami Y, Klein TW, Newton C, Djeu JY, Specter S, Friedman H (1988b) Suppression by
delta-9-tetrahydrocannabinol of interleukin 2-induced lymphocyte proliferation and
lymphokine-activated killer cell activity. Int J Immunopharmacol 10:485–488
Killestein J, Hoogervorst EL, Reif M, Blauw B, Smits M, Uitdehaag BM, Nagelkerken L,
Polman CH (2003) Immunomodulatory effects of orally administered cannabinoids in
multiple sclerosis. J Neuroimmunol 137:140–143